HOUSTON, July 22, 2020 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary aesthetic platform technology,
today announced Dr. Elizabeth Tanzi,
lead investigator on Soliton's pivotal cellulite clinical trial and
member of Soliton's Scientific Advisory Board, will present the
results from Soliton's pivotal cellulite trial at the 2020 Virtual
Music City Symposium for Cosmetic Advances & Laser Education
("SCALE") on Saturday, July
25th at 3:40 p.m.
CST.
![Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company’s first planned commercial product is designed to use rapid pulses of designed acoustic shockwaves in conjunction with existing lasers to accelerate the removal of unwanted tattoos (RAP device). In addition, higher energy versions of acoustic pulse devices are in early stages of development for potential stand-alone treatment of cellulite and other indications. (PRNewsfoto/Soliton, Inc.) Soliton, Inc. is a medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company’s first planned commercial product is designed to use rapid pulses of designed acoustic shockwaves in conjunction with existing lasers to accelerate the removal of unwanted tattoos (RAP device). In addition, higher energy versions of acoustic pulse devices are in early stages of development for potential stand-alone treatment of cellulite and other indications. (PRNewsfoto/Soliton, Inc.)](https://mma.prnewswire.com/media/871205/Soliton_Logo.jpg)
"We are excited Dr. Tanzi selected Soliton's pivotal cellulite
clinical trial results to present at the premier Music City
aesthetic symposium as it provides further credibility to our
innovative RAP device and the results of our pivotal cellulite
trial, which demonstrated an average reduction of 32.5% in
Cellulite Severity Score. Following initial presentation at AAD
2020 VMX Virtual Conference last month, we are thankful for the
opportunity to more broadly share with this physician and
dermatology community the outcomes regarding the potential of our
RAP device to improve the appearance of cellulite," stated
Christopher Capelli, MD, founder,
President and CEO of Soliton.
Join our more than 200K
subscribers here to follow the
Company: https://soly-investors.com
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson
Cancer Center. The Company's first FDA cleared commercial product
will use rapid pulses of acoustic shockwaves as an accessory to
lasers for the removal of unwanted tattoos. The Company is based in
Houston, Texas, and is actively
engaged in bringing the Rapid Acoustic Pulse ("RAP") device to the
market. The Company believes this "Soliton" method has the
potential to lower tattoo removal costs for patients, while
increasing profitability to practitioners, compared to current
laser removal methods. Soliton is investigating potential
additional capabilities of the RAP technology in clinical and
preclinical testing, including the potential to improve the
appearance of cellulite by creating mechanical stress at the
cellular level and inducing significant collagen growth and the
potential to treat keloid and hypertrophic scars by targeting the
stiffened environment in the intracellular matrix.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of Dr. Tanzi to
present the cellulite pivotal results at SCALE. These
statements relate to future events, future expectations, plans and
prospects. Although Soliton believes that the expectations
reflected in such forward-looking statements are reasonable as of
the date made, expectations may prove to have been materially
different from the results expressed or implied by such
forward-looking statements. Soliton has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed in our SEC filings,
including under the heading "Item 1A. Risk Factors" in the Form
10-K for year ended December 31, 2019
we filed with the SEC and updated from time to time in our Form
10-Q filings and in our other public filings with the SEC. Any
forward-looking statements contained in this release speak only as
of its date. Soliton undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-announces-presentation-of-pivotal-cellulite-data-at-virtual-music-city-symposium-for-cosmetic-advances--laser-education-scale-301097699.html
SOURCE Soliton, Inc.